RESUMO
A novel series of DGAT-1 inhibitors was discovered from an oxadiazole amide high throughput screening (HTS) hit. Optimisation of potency and ligand lipophilicity efficiency (LLE) resulted in a carboxylic acid containing clinical candidate 53 (AZD3988), which demonstrated excellent DGAT-1 potency (0.6 nM), good pharmacokinetics and pre-clinical in vivo efficacy that could be rationalised through a PK/PD relationship.
Assuntos
Diacilglicerol O-Aciltransferase/antagonistas & inibidores , Inibidores Enzimáticos/síntese química , Hipoglicemiantes/síntese química , Oxidiazóis/síntese química , Animais , Diabetes Mellitus/tratamento farmacológico , Diacilglicerol O-Aciltransferase/metabolismo , Cães , Desenho de Fármacos , Avaliação Pré-Clínica de Medicamentos , Inibidores Enzimáticos/farmacocinética , Inibidores Enzimáticos/farmacologia , Meia-Vida , Ensaios de Triagem em Larga Escala , Humanos , Hipoglicemiantes/farmacocinética , Hipoglicemiantes/farmacologia , Ligantes , Camundongos , Obesidade/tratamento farmacológico , Oxidiazóis/farmacocinética , Relação Quantitativa Estrutura-Atividade , RatosRESUMO
Inhibition of DGAT-1 is increasingly seen as an attractive mechanism with the potential for treatment of obesity and other elements of the metabolic syndrome. We report here a bicyclooctaneacetic acid derivative in the pyrimidinooxazine structural class of DGAT-1 inhibitors that has good potency, selectivity, and pharmacokinetic characteristics across a variety of species. This compound is an effective inhibitor of DGAT-1 in both intestinal and adipose tissue, which results in a reduction in body weight or body weight gain following oral administration in both mouse and rat models of dietary-induced obesity.
Assuntos
Diacilglicerol O-Aciltransferase/antagonistas & inibidores , Inibidores Enzimáticos/farmacologia , Oxazinas/farmacologia , Pirimidinas/farmacologia , Administração Oral , Animais , Peso Corporal/efeitos dos fármacos , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/uso terapêutico , Feminino , Humanos , Espectroscopia de Ressonância Magnética , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Obesidade/tratamento farmacológico , Ratos , Ratos Wistar , Espectrometria de Massas por Ionização por ElectrosprayRESUMO
BACKGROUND: Mice that lack acyl CoA:diacylglycerol acyltransferase (Dgat1-/- mice) are reported to have a reduced body fat content and improved glucose tolerance and insulin sensitivity. Studies so far have focussed on male null mice fed a high fat diet and there are few data on heterozygotes. We compared male and female Dgat1-/-, Dgat1+/- and Dgat1+/+ C57Bl/6 mice fed on either standard chow or a high fat diet. RESULTS: Body fat content was lower in the Dgat1-/- than the Dgat1+/+ mice in both experiments; lean body mass was higher in male Dgat1-/- than Dgat1+/+ mice fed on the high fat diet. Energy intake and expenditure were higher in male Dgat1-/- than Dgat1+/+ mice; these differences were less marked or absent in females. The body fat content of female Dgat1+/- mice was intermediate between that of Dgat1-/- and Dgat1+/+ mice, whereas male Dgat1+/- mice were similar to or fatter than Dgat1+/+ mice. Glucose tolerance was improved and plasma insulin reduced in Dgat1-/- mice fed on the high fat diet, but not on the chow diet. Both male and female Dgat1+/- mice had similar glucose tolerance to Dgat1+/+ mice. CONCLUSION: These results suggest that although ablation of DGAT1 improves glucose tolerance by preventing obesity in mice fed on a high fat diet, it does not improve glucose tolerance in mice fed on a low fat diet.
